ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Low-dose lipopolysaccharide modulates the RNF4-induced SUMO-dependent degradation of Nrf2 to mitigate oxidative stress in spinal cord injury.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Spinal cord injury (SCI) represents a significant medical challenge, with limited therapeutic options and suboptimal outcomes. This study investigates the therapeutic potential of low-dose lipopolysaccharide (LD-LPS) in SCI, aiming to elucidate the underlying molecular mechanisms. An in vivo SCI model was established, and the effects of LD-LPS, 2-D08, and RNF4 on nerve injury were assessed using Nissl staining, dihydroethidium (DHE) staining, and Basso, Beattie, Bresnahan (BBB) locomotor scores. In vitro models of SCI were also developed, treated with LD-LPS, and transfected with si-KEAP1, si-RNF4, or RNF4-overexpression vectors. RNF4 and Nrf2 expression levels were measured via immunofluorescence staining, reverse transcription quantitative polymerase chain reaction (RT-qPCR), and Western blot analysis. Cell viability and reactive oxygen species (ROS) production were assessed using the Cell Counting Kit-8 (CCK-8) and 2, 7-dichlorodihydrofluorescein diacetate (DCFH-DA) assays. Oxidative stress was evaluated by measuring the activities of catalase (CAT), superoxide dismutase (SOD), and glutathione (GSH). Immunoprecipitation was used to determine the SUMOylation level of SUMO-Nrf2, and the interaction between RNF4 and Nrf2 was analyzed through Split-BioID. LD-LPS demonstrated significant neuroprotective effects by mitigating oxidative stress following SCI. Mechanistically, RNF4 was identified as a critical regulator of Nrf2 SUMOylation, modulating its nuclear translocation. Genetic silencing of RNF4, in conjunction with LD-LPS treatment, alleviated SCI-induced neuronal damage, reduced oxidative stress, and promoted motor function recovery. Conversely, RNF4 overexpression exacerbated SCI injury, highlighting its central role in Nrf2 degradation. These results suggest that LD-LPS mitigates ROS production in SCI by modulating RNF4-mediated SUMOylation of Nrf2. These findings provide initial evidence for the molecular mechanisms underlying LD-LPS preconditioning in SCI.
Indexed as
Identifiers
40616678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.